Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20226 (
TATA-binding protein
)
1,297
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The following hypothesis has been proposed: IF an SNP can significantly increase the expression of an oncogene by increasing the affinity of the
TATA-binding protein
(
TBP
) to its promoter, THEN this SNP can also reduce the apparent bioactivity of inhibitors of this oncogene during antitumor chemotherapy and vice versa. In the context of this hypothesis, the previously proposed method (http://beehive.bionet.nsc. ru/cgi-bin/mgs/tatascan/start.pl) was applied to analyze all SNPs found within the [-70; -20] regions (which harbor all proven
TBP
-binding sites) of the promoters of
VEGFA
, EGFR, ERBB2, IGF1R, FLT1, KDR, and MET oncogenes according to the human reference genome, hg19. For 83% of these SNPs, their effect on
TBP
affinity to the oncogene promoters required for assembly of preinitiation complexes was not significant. rs36208385, rs36208384, rs370995111, rs372731987, rs111811434, rs369547510, rs76407893, rs369728300, and rs72001900 can potentially serve as SNP markers to reduce the apparent bioactivity of oncogene inhibitors, while rs141092704, rs184083669, rs145139616, rs200697953, rs187746433, rs199730913, rs377370642, rs114484350, rs374921120, rs146790957, rs376727645, and rs72001900 can be the markers for enhancing this activity.
...
PMID:[Hypothetical SNP Markers That Significantly Affect the Affinity of the TATA-Binding Protein to VEGFA, ERBB2, IGF1R, FLT1, KDR, and MET Oncogene Promoters as Chemotherapy Targets]. 2702 22
The
TATA-binding protein
(
TBP
) plays a central role in eukaryotic gene transcription. Given its key function in transcription initiation,
TBP
was initially thought to be an invariant protein. However, studies showed that
TBP
expression is upregulated by oncogenic signaling pathways. Furthermore, depending on the cell type, small increases in cellular
TBP
amounts can induce changes in cellular growth properties towards a transformed phenotype. Here we sought to identify the specific
TBP
-regulated gene targets that drive its ability to induce tumorigenesis. Using microarray analysis, our results reveal that increases in cellular
TBP
concentrations produce selective alterations in gene expression that include an enrichment for genes involved in angiogenesis. Accordingly, we find that
TBP
levels modulate
VEGFA
expression, the master regulator of angiogenesis. Increases in cellular
TBP
amounts induce
VEGFA
expression and secretion to enhance cell migration and tumor vascularization.
TBP
mediates changes in
VEGFA
transcription requiring its recruitment at a hypoxia-insensitive proximal TSS, revealing a mechanism for VEGF regulation under non-stress conditions. The results are clinically relevant as
TBP
expression is significantly increased in both colon adenocarcinomas as well as adenomas relative to normal tissue. Furthermore,
TBP
expression is positively correlated with
VEGFA
expression. Collectively, these studies support the idea that increases in
TBP
expression contribute to enhanced
VEGFA
transcription early in colorectal cancer development to drive tumorigenesis.
...
PMID:Elevated TATA-binding protein expression drives vascular endothelial growth factor expression in colon cancer. 2841 73